Price T Rowe Associates Inc. MD Increases Stock Position in Glaukos Co. (NYSE:GKOS)

Price T Rowe Associates Inc. MD boosted its position in Glaukos Co. (NYSE:GKOS - Free Report) by 13.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,182 shares of the medical instruments supplier's stock after buying an additional 4,227 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.06% of Glaukos worth $5,276,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Barclays PLC lifted its holdings in shares of Glaukos by 394.4% in the 3rd quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock worth $11,686,000 after purchasing an additional 71,556 shares in the last quarter. Tidal Investments LLC grew its holdings in shares of Glaukos by 83.1% during the third quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier's stock valued at $1,942,000 after buying an additional 6,767 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Glaukos by 80.1% during the third quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier's stock worth $2,031,000 after acquiring an additional 6,948 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Glaukos by 28.3% in the 4th quarter. GAMMA Investing LLC now owns 2,213 shares of the medical instruments supplier's stock worth $332,000 after acquiring an additional 488 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new stake in shares of Glaukos in the 4th quarter worth about $3,679,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Price Performance

NYSE GKOS traded up $2.46 during trading on Thursday, reaching $90.70. The company's stock had a trading volume of 771,359 shares, compared to its average volume of 678,486. The firm has a fifty day moving average of $95.68 and a 200 day moving average of $127.93. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71. The stock has a market capitalization of $5.18 billion, a PE ratio of -31.60 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same period last year, the firm posted ($0.70) earnings per share. Glaukos's quarterly revenue was up 24.6% on a year-over-year basis. Analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on GKOS shares. Piper Sandler cut their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. Needham & Company LLC reduced their price objective on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Stifel Nicolaus dropped their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Mizuho decreased their price target on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday, April 16th. Finally, Truist Financial reissued a "buy" rating and issued a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, Glaukos presently has an average rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.